[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345284-105":59,"doc-detail-345284-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","extrachromosomal-dna-in-solid-tumorslandscape-immune-effects-and-resistance-to-targeted-therapy","Extrachromosomal DNA in Solid Tumors—Landscape, Immune Effects, and Resistance to Targeted Therapy","","Extrachromosomal DNA (ecDNA) is a major mechanism that amplifies oncogenes and drives progression in solid cancers. This review integrates emerging mechanistic, genomic, and immunologic findings across multiple tumor types, explaining how ecDNA shapes immune escape and resistance to targeted therapy. EcDNA consists of acentromeric circular elements that act as transcriptional hubs, alter enhancer–promoter interactions, and cycle in copy number, promoting intratumoral heterogeneity. It frequently carries recurrent oncogenic cargos such as EGFR, MYC, ERBB2/HER2, and CCND1, which can switch with intrachromosomal HSRs under treatment pressure. Evidence links ecDNA to an immune-cold phenotype with reduced antigen presentation and diminished checkpoint inhibitor responsiveness. The review outlines diagnostic and translational approaches including liquid biopsy detection and spatial mapping, and proposes a clinical framework combining ecDNA profiling, longitudinal monitoring, and immune microenvironment assessment to guide precision therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/extrachromosomal-dna-in-solid-tumorslandscape-immune-effects-and-resistance-to-targeted-therapy/345284/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/extrachromosomal-dna-in-solid-tumorslandscape-immune-effects-and-resistance-to-targeted-therapy/345284.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is ecDNA and why does it matter in solid tumors?","Question",{"text":112,"@type":113},"Extrachromosomal DNA (ecDNA) comprises large circular elements outside chromosomes. It drives oncogene amplification and tumor progression, supporting intratumoral heterogeneity and therapy resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can ecDNA contribute to immune escape and resistance to immune checkpoint inhibitors?",{"text":117,"@type":113},"The review links ecDNA to an immune-cold phenotype with downregulated antigen presentation. This is associated with decreased responsiveness to immune checkpoint inhibitors.",{"name":119,"@type":110,"acceptedAnswer":120},"How can ecDNA be detected for clinical and translational applications?",{"text":121,"@type":113},"The review emphasizes incorporating ecDNA detection through liquid biopsy. It also highlights spatial mapping of tumor topology to understand how ecDNA relates to tumor organization.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345284,1791085993,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Tech Science Press  \n[https://doi. org/10.32604/or.2026.075916](https://doi. org/10.32604/or.2026.075916)  \nREVIEW  \nExtrachromosomal DNA in Solid Tumors—Landscape, Immune Effects, and Resistance to Targeted Therapy  \nOmar Badran1,2, * and Siraj Attarya3  \n1 Department of Oncology, Emek Medical Center, Afula, Israel  \n2 Technion Integrated Cancer Center, Faculty of Medicine, Technion, Haifa, Israel  \n3 The Arab National Society for Health Research and Services, The Galilee Society, Shafa Amr, Israel  \n*[Corresponding Author: Omar Badran. Email: omar302702@gmail.com](Corresponding Author: Omar Badran. Email: omar302702@gmail.com)  \n[Received: 11 November 2025](Received: 11 November 2025); [Accepted: 21 February 2026](Accepted: 21 February 2026); [Published: 22 April 2026](Published: 22 April 2026)  \nABSTRACT: Extrachromosomal DNA (ecDNA) constitutes a principal factor in the amplification of oncogenesand the progression of tumors in solid malignancies. This review synthesizes emerging mechanistic, genomic, and immunologic evidence across multiple tumor types, including glioblastoma, lung, breast, gastrointestinal, hepatobiliary, urothelial, prostate, gynecologic, pediatric, and head-and-neck cancers, with the goal of clarifying the role of ecDNA in immune escape and therapy resistance and outlining its translational implications for precision oncology. ecDNA comprises substantial acentromeric circular elements that serve as transcriptional hubs, modulate enhancer– promoter interactions, and undergo dynamic copy-number cycling, thereby fostering intratumoral heterogeneity and resistance to therapy. Recurrent oncogenic cargos, including epidermal growth factor receptor (EGFR), v-myc avian myelocytomatosis viral oncogene homolog (MYC), erb-b2 receptor tyrosine kinase 2, also known as human epidermal growth factor receptor 2 (ERBB2/HER2), and cyclin D1 (CCND1), are frequently located in ecDNA. They can interconvert with intrachromosomal homogeneously staining regions (HSRs) under treatment pressure. Emerging evidence links ecDNA to an immune-cold phenotype, characterized by downregulation of antigen presentation and decreased responsiveness to immune checkpoint inhibitors. We further emphasize diagnostic and translational methodologies that incorporate ecDNA detection through liquid biopsy and the spatial mapping of tumor topology. Finally, we propose a comprehensive clinical implementation framework that integrates ecDNA profiling, longitudinal monitoring, and immune microenvironment assessment to guide precision therapy. Gaining a deeper understanding of ecDNA biology has the potential to ultimately transform it from merely a prognostic biomarker into a targetable element within cancer therapy.  \nKEYWORDS: Extrachromosomal DNA (ecDNA); double minutes; enhancer hijacking; immune-cold tumors; targeted-therapy resistance; liquid biopsy  \n1 Introduction  \nOver the past century, cancer care has undergone a profound therapeutic evolution [1–4] . The earliest treatment paradigm relied almost exclusively on surgical resection, aimed at removing localized tumors before the onset of metastatic spread [5,6] . As systemic disease control emerged as a critical unmet need, the mid-20th century ushered in the cytotoxic chemotherapy era, providing the first tools capable of addressing disseminated malignancy, albeit with limited precision and substantial toxicity to healthy tissues [7–11] . The subsequent decades witnessed the advent of targeted therapies, enabled by the molecular characterization of oncogenic drivers, which transformed subsets of cancers, such as Epidermal Growth  \nCopyright © 2026 The Authors. Published by Tech Science Press. This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nFactor Receptor (EGFR)-mutant lung cancer, Breakpoint Cluster Region–Abelson (BCR-ABL)–rearran","cbCailJEjh5Mhurc","https://ap.wps.com/l/cbCailJEjh5Mhurc","pdf",12984125,34,"English","# Abstract\n# Key Concepts in ecDNA Biology\n## Transcriptional hubs and enhancer–promoter remodeling\n## Copy-number cycling and tumor heterogeneity\n# oncogenic cargoes and treatment pressure\n## EGFR, MYC, ERBB2/HER2, and CCND1\n## Interconversion with HSRs\n# Immunologic consequences\n## Immune-cold phenotype and immune escape\n# Diagnostic and translational strategies\n## Liquid biopsy detection\n## Spatial mapping of tumor topology\n# Clinical implementation framework","[{\"question\":\"What is ecDNA and why does it matter in solid tumors?\",\"answer\":\"Extrachromosomal DNA (ecDNA) comprises large circular elements outside chromosomes. It drives oncogene amplification and tumor progression, supporting intratumoral heterogeneity and therapy resistance.\"},{\"question\":\"How can ecDNA contribute to immune escape and resistance to immune checkpoint inhibitors?\",\"answer\":\"The review links ecDNA to an immune-cold phenotype with downregulated antigen presentation. This is associated with decreased responsiveness to immune checkpoint inhibitors.\"},{\"question\":\"How can ecDNA be detected for clinical and translational applications?\",\"answer\":\"The review emphasizes incorporating ecDNA detection through liquid biopsy. It also highlights spatial mapping of tumor topology to understand how ecDNA relates to tumor organization.\"}]","Extrachromosomal DNA in Solid Tumors—Landscape, Immune Effects, and Resistance to Targeted Therapy | PDF",1790057113,86,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b71830a70b954cfb7c4fbb0e2a3e54bd.webp",983,1271,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e3605e473ccd8da289058ed10f9e605.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6112f88cd33bdee20150ee9019e458f.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91ef7dad2de12a46dbedc73c5fd47051.webp",980,1267]